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Background: Coronavirus disease 2019 is a pandemic with no spe-
cific therapeutic agents or vaccination. Small published case series 
on critically ill adults suggest improvements in clinical status with 
minimal adverse events when patients receive coronavirus disease 
2019 convalescent plasma, but data on critically ill pediatric patients 
are lacking. We report a series of four critically ill pediatric patients 
with acute respiratory failure who received coronavirus disease 2019 
convalescent plasma as a treatment strategy for severe disease.
Case Summary: Patients ranged in age from 5 to 16 years old. All 
patients received coronavirus disease 2019 convalescent plasma 
within the first 26 hours of hospitalization. Additional disease modi-
fying agents were also used. All patients made a full recovery and 
were discharged home off of oxygen support. No adverse events 
occurred from the coronavirus disease 2019 convalescent plasma 
transfusions.
Conclusion: Coronavirus disease 2019 convalescent plasma is a fea-
sible therapy for critically ill pediatric patients infected with severe 
acute respiratory syndrome coronavirus 2. Well-designed clinical tri-
als are necessary to determine overall safety and efficacy of coro-
navirus disease 2019 convalescent plasma and additional treatment 
modalities in pediatric patients.
Key words: acute respiratory failure; convalescent plasma; coronavirus 
disease 2019; coronavirus disease 2019 convalescent plasma; 
pediatric intensive care unit; pediatrics
BACKGROUND
Since its origin in Wuhan, China, the epidemic of severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly 
spread worldwide, leading the World Health Organization to 
declare coronavirus disease 2019 (COVID-19) a pandemic (1, 2). 
As of June 19, 2020, the virus has caused over 450,000 deaths 
worldwide and infected patients in more than 215 countries (2). 
Several published studies suggest that COVID-19 illness might 
have a milder course in pediatric patients (3–6), but severe disease 
does occur (7).
There is currently no specific treatment or vaccine for 
COVID-19. Multiple therapies including antivirals and immuno-
modulators are under investigation (8, 9). Convalescent plasma 
has been used to treat other high-risk viral pathogens, and its use 
for COVID-19 is being explored (10–13). Several small case series 
in critically ill adults receiving COVID-19 convalescent plasma 
(CCP) suggest improvement in patient clinical status with mini-
mal adverse events (8–10, 14–16). A larger analysis of 5,000 adult 
patients with severe COVID-19 infection suggested safety in hos-
pitalized patients (17). There are no published studies regarding 
the use of CCP in critically ill pediatric patients. In this report, we 
describe a single-center’s initial experience with CCP in four criti-
cally ill pediatric patients with SARS-CoV-2.
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CASE SUMMARY
All four patients were admitted to the PICU with a diagnosis of 
SARS-CoV-2 and acute respiratory failure requiring high-flow 
nasal cannula (HFNC) at admission. Table  1 summarizes key 
demographic features of the four patients, the timing of CCP 
therapy, and additional therapeutic modalities employed. Three 
of the four patients received CCP obtained via apheresis from 
donors donating to the University of North Carolina Blood 
Donation Center. One patient received CCP from an outside sup-
plier. Donors met Food and Drug Administration (FDA) require-
ments for eligibility by both standard blood donor and CCP 
donor criteria. Donors had documented SARS-CoV-2 infection 
TABLE 1. Demographics and Clinical Characteristics of Four Critically Ill Pediatric Patients With 
Coronoavirus Disease 2019 Treated With Convalescent Plasma
Patients 1 2 3 4
Age (yr, mo) 15, 9 16, 4 5, 11 12 , 6
Sex Male Male Female Female
Body mass index (kg/m2) 35.97 37.4 20.32 44.92
Ethnicity Hispanic Asian Hispanic Hispanic
Blood type O positive A positive O positive A positive
Comorbidities Obesity Obesity None Obesity, asthma








Hospital LOS (d) 10 7 24 11
ICU LOS (d) 9 4 15 7
Laboratories at admission
C-reactive protein (mg/L) 357.9 31 179 60.3
Erythrocyte sedimentation rate (mm/hr) 60 64 32 54
Fibrinogen (mg/dL) 926 504 547 486
Ferritin (ng/mL) 340 803 388 235
Lactate dehydrogenase (U/L) 1,163 1,467 626 1,244
d-dimer (ng/mL) 1,004 459 1,979 < 150
WBC (× 109/L) 12.8 3.7 14.7 5.2
Absolute lymphocyte count (× 109/L) 0.8 1.1 0.7 0.5
Absolute neutrophil count (× 109/L) 11.6 2.1 13.5 4.5
Platelet count (× 109/L) 124 272 157 237
Troponin I (ng/mL) < 0.034 < 0.034 0.599 < 0.034
Pro-b-type natriuretic peptide (pg/mL) 256 65 10,400 12
Creatinine (mg/dL) 0.77 0.71 0.32 0.37
Aspartate aminotransferase 
(U/L)|Alanine aminotransferase (U/L)
39|117 37|24 94|86 56|46
Hospital day of CCP 3 2 2 1
CCP units transfused 2 (same donor) 2 10 mL/kg 2 (separate donors)
Receptor-binding domain endpoint titer 1:160 Unknown 1:1,280 Unit 1 = 1: 2,560,
Unit 2 = 1:640
Additional therapies Remdesivir, 
anakinra
Remdesivir Remdesivir, IV immunoglobulin, 
steroids, anakinra
Remdesivir, steroids
Outcome Discharged home 
7 d after CCP
Discharged home 
5 d after CCP
Discharged home 
23 d after CCP
Discharged home 
10 d after CCP
CCP = coronavirus disease 2019 convalescent plasma, HFNC = high-flow nasal cannula, LOS = length of stay.
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by a diagnostic test (e.g., nasal swab polymerase chain reaction 
[PCR]) or a positive serologic test for SARS-CoV-2 antibodies. 
All donors had complete resolution of symptoms for at least 14 
days prior to donation. For each case, a single-patient emergency 
Investigational New Drug (E-IND) application was submitted to 
the FDA and approved. Parental consent was obtained in each 
case prior to administration of CCP. Donor units obtained at the 
University of North Carolina Blood Donation Center were tested 
for the presence of anti-SARS-CoV-2 antibodies using a custom-
ized enzyme-linked immunosorbent assay binding assay targeted 
to the receptor-binding domain (RBD) of the SARS-CoV-2 spike 
protein (18).
Case 1
A 15-year-old obese, Hispanic male was transferred to the PICU 
from an outside hospital due to rapidly progressing acute respira-
tory failure secondary to SARS-CoV-2 which was diagnosed by 
viral PCR. The patient had presented to the hospital with 7 days of 
fever (temperature 40.2°C), worsening cough, shortness of breath, 
chest tightness, nausea, vomiting, and poor per os (PO) intake. 
He initially required only low-flow nasal cannula but quickly 
escalated to HFNC. On arrival to the PICU, he was febrile and 
tachycardic with normal blood pressure and perfusion. He was 
tachypneic and in moderate respiratory distress on 30 L HFNC, 
100% Fio2. Admission chest radiograph (CXR) demonstrated 
hypoinflated lungs with patchy perihilar and left midlung opaci-
ties compatible with viral pneumonia and history of confirmed 
COVID-19. Laboratories were significant for elevated C-reactive 
protein (CRP), erythrocyte sedimentation rate (ESR), ferritin, 
lactate dehydrogenase (LDH), fibrinogen, and d-dimer, as well 
as lymphopenia. Troponin, pro-b-type natriuretic peptide (pro-
BNP), and cardiac function were normal. Table 1 provides admis-
sion laboratory values.
On the day of transfer from the outside hospital, he had been 
started on remdesivir which was continued for 7 days (hospital 
day [HD] 1–HD7) and ultimately stopped due to rising ALT. In 
the setting of increasing HFNC requirements, the patient received 
two units of CCP from the same donor (RBD binding titer 1:160) 
on HD3 (26 hr after admission). He had no adverse effects from 
the transfusion. Figure 1 illustrates the change in Fio2, fever 
curve, and CRP following CCP transfusion. Following receipt of 
CCP, he had improvement in some inflammatory markers (CRP), 
but others continued to increase (ferritin and platelets), and his 
respiratory support maxed at 60 L HFNC, 100% Fio2. Therefore, 
on HD4, he was started on IV anakinra which was continued for 
6 days. Respiratory requirements plateaued at 50–60 L HFNC and 
Figure 1. Trend over time in Fio2, temperature, and C-reactive protein (CRP) of four critically ill pediatric patients with coronavirus disease 2019 (COVID-19) 
treated with COVID-19 convalescent plasma (CCP). Dashed red lines indicate time of CCP administration. Patient outcomes as of end of study observation 
given in parentheses.
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100% Fio2 until HD6 when he slowly started to wean support. He 
was stable on room air on HD9 and discharged home on HD10 (7 
d following CCP administration). Figure 2 shows a timeline of his 
hospital course.
Case 2
A 16-year-old obese, Asian male was transferred to the PICU from 
an outside hospital due to hypoxia from SARS-CoV-2 which was 
diagnosed by viral PCR. The patient had presented to the hospi-
tal with 14 days of symptoms including fever, worsening cough, 
shortness of breath, rhinorrhea, chest pain, malaise, nausea, and 
poor PO intake. He also complained of new onset hemoptysis. On 
arrival to the PICU, he was hemodynamically stable with normal 
heart rate, blood pressure, and perfusion. He was tachypneic with 
mild respiratory distress on 6 L HFNC, Fio2 100%. Admission CXR 
demonstrated hazy and patchy bilateral pulmonary infiltrates con-
sistent with a viral pneumonia. Laboratories were significant for 
elevated CRP, ESR, ferritin, LDH, fibrinogen, and d-dimer, as well 
as lymphopenia. Troponin, pro-BNP, 
and cardiac function were normal. 
Table  1 provides admission labora-
tory values.
On the evening of transfer, the 
patient’s respiratory status quickly 
worsened, and respiratory support 
was escalated to a maximum of 50 L 
HFNC, Fio2 100%. In the setting of 
increasing HFNC requirements, the 
patient received two units of CCP 
(from an outside vendor) on HD2 
(14 hr after admission). He had no 
adverse effects from the transfusion. 
Figure 1 illustrates the change in Fio2, 
fever curve, and CRP following CCP 
transfusion. Remdesivir was also 
started on HD2 and continued for a 
5-day course. Following CCP and ini-
tiation of remdesivir, he had improve-
ment in oxygen requirement and was
able to wean down on his HFNC flow
and Fio2. He was stable on room air
on HD6 and discharged home on
HD7 (5 d following CCP administra-
tion). Figure 2 shows a timeline of his
hospital course.
Case 3
A previously healthy, 5-year-old 
Hispanic female was transferred to 
the PICU from an outside hospital 
emergency department due to acute 
respiratory failure, fluid-refractory 
hypotension, and elevated inflamma-
tory markers in the setting of SARS-
CoV-2 which was diagnosed by viral 
PCR. The patient presented to the 
outside hospital with 5 days of fever, abdominal pain, dysuria, 
nausea, vomiting, and new onset erythematous rash on her chest 
and abdomen. Laboratories were significant for elevated CRP, 
ESR, ferritin, fibrinogen, and d-dimer. She also had elevated tro-
ponin and pro-BNP. Table 1 provides admission laboratory values.
At admission to our PICU, she was afebrile but tachycardic and 
hypotensive on a high-dose epinephrine infusion (0.2 µg/kg/min). 
She was also tachypneic but maintaining normal oxygen satura-
tions on 6 L HFNC, Fio2 100%. She was alert and oriented without 
focal neurologic deficits. Echocardiogram at admission revealed 
mildly decreased systolic function and mild left anterior descend-
ing coronary artery dilation. She remained hypotensive despite 
stress-dose steroids and the addition of a norepinephrine infu-
sion. Additionally, she had worsening hypoxia despite escalation 
in HFNC support. Less than 3 hours after admission, she was intu-
bated due to persistent hypoxemia and hypotension. Initial oxy-
genation index was 19, indicating severe acute respiratory distress 
syndrome (ARDS). Given escalating support, the patient received 
Figure 2. Timeline of hospital course including treatment strategies employed, respiratory support, and 
outcome. BiPAP = bilevel positive airway pressure, CCP = coronavirus disease 2019 convalescent plasma, 
CMV = conventional mechanical ventilation, ECMO = veno-arterial extracorporeal membrane oxygenation,  
F = female, HFNC = high-flow nasal cannula, IVIG = intravenous immunoglobulin, m = months, M = male,  
NC = nasal cannula, OSH = outside hospital, y = years.
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10 mL/kg of CCP (RBD binding titer 1:1,280) on HD2 (19 hr after 
admission) and was also started on remdesivir. She had no adverse 
effects from the transfusion. Figure 1 illustrates the change in Fio2, 
fever curve, and CRP following CCP transfusion. Remdesivir was 
continued for a total of 5 days (HD2–HD6).
A second echocardiogram obtained nine hours after admission 
revealed severely diminished left ventricular systolic function. On 
HD2 (< 24 hr after admission), she was cannulated to venoarte-
rial extracorporeal membrane oxygenation (VA ECMO) for car-
diogenic shock and myocarditis. SARS-CoV-2 immunoglobulin G 
(IgG) assay (Abbott Laboratories, Abbott Park, IL) testing which 
was collected prior to the administration of CCP or IV immuno-
globulin (IVIG), returned positive on HD2; these results did not 
return until after the administration of CCP. This disease process 
appeared more consistent with multisystem inflammatory syn-
drome in children (MIS-C) than with acute COVID-19 infection. 
Following cannulation on HD2, she also received high-dose ste-
roids, IVIG, and was started on IV anakinra. Cardiac function and 
respiratory status improved while on VA ECMO, and the patient 
was decannulated on HD9 (extracorporeal membrane oxygen-
ation day 7). The patient was extubated to HFNC on HD10 and 
weaned to room air on HD13. She was transferred out of the PICU 
on HD15 and was discharged home on HD24 (23 d following CCP 
administration). Figure 2 shows a timeline of her hospital course.
Case 4
A 12-year-old obese, Hispanic female with a history of asthma was 
transferred to our PICU from an outside hospital due to short-
ness of breath and a known diagnosis of SARS-Cov-2 diagnosed 
by viral PCR. She was also group A streptococcus positive by oro-
pharyngeal swab at the outside facility. The patient presented to 
the hospital with seven days of fever, cough, and fatigue and three 
days of shortness of breath. On arrival to the PICU, she was afe-
brile, tachycardic and tachypneic but with normal blood pressure 
and perfusion. CXR showed bilateral patchy opacities without 
pleural effusions consistent with viral pneumonia. Laboratories 
were significant for elevated CRP, LDH, and ferritin as well as lym-
phopenia. Troponin, pro-BNP and screening electrocardiogram 
were normal. Table 1 provides admission laboratory values.
On arrival, she demonstrated dyspnea on 45 L HFNC, Fio2 
100%, and was escalated to bilevel positive airway pressure (BiPAP) 
therapy. On the night of admission (HD1, 2 hr after admission), 
she received two units of CCP (RBD binding titer unit 1 = 1:2,560, 
unit 2 = 1:640). She had no adverse effects from the transfusion. 
Figure 1 illustrates the change in Fio2, fever curve, and CRP fol-
lowing CCP transfusion. Remdesivir was also started on HD1 and 
continued for 10 days (HD1–HD10). She received ceftriaxone 
for 5 days to treat strep pharyngitis. On HD3, she had worsening 
respiratory distress and progressed to intubation. She initially had 
difficulty oxygenating requiring high mean airway pressures with 
an initial oxygenation index of 18, indicating severe ARDS. IV 
methylprednisolone was started at the time of intubation. Mean 
airway pressures were able to be weaned, and she was extubated 
to BiPAP on HD6 and quickly weaned to HFNC on the same day. 
She was transferred out of the PICU on low-flow nasal cannula on 
HD7 and weaned to room air on HD9. She was discharged home 
on HD11 (10 d following CCP administration). Figure 2 shows a 
timeline of her hospital course.
DISCUSSION
The global pandemic of SARS-CoV-2 has led to substantial world-
wide morbidity and mortality. Although many treatment strate-
gies are being studied, there are currently no vaccines or specific 
drugs available for the treatment of severe COVID-19 (10, 11). 
Convalescent plasma has been successfully used for the treatment 
of other viral infections including SARS-CoV, Middle East respira-
tory syndrome, influenza A (H1N1), and Ebola (11, 12). However, 
definitive clinical evidence showing the efficacy of convalescent 
plasma is scarce and inconsistent with some studies showing ben-
efit (11, 13, 19), whereas others have not (20). Due to the rapidly 
progressing pandemic, as well as no definitive treatment strategies 
or vaccination, the FDA allowed the use of convalescent plasma 
with an E-IND to treat critically ill patients with life-threatening 
diseases including respiratory failure and shock (21).
A few small case series, ranging from one to 10 critically ill adult 
patients, have been published that suggest improvement in patient 
clinical status with minimal adverse events when patients receive 
convalescent plasma (8–10, 14–16). A larger randomized control 
trial demonstrated trends toward more favorable outcomes but did 
not reach statistically significant differences when comparing CCP 
administration with standard supportive care in adult hospitalized 
patients with benefit limited to those with severe but not life-threat-
ening COVID-19 (22). However, this trial terminated early due to 
inability to enroll enough patients and may have not been powered 
to demonstrate statistical significance (22, 23). Shen et al (9) showed 
improvement in the Sequential Organ Failure Assessment score, 
Pao2/Fio2 ratio, and viral loads within 12 days of administration of 
CCP in five critically ill adults. Duan et al (15) demonstrated feasi-
bility of CCP in 10 critically ill adults and showed improvement in 
clinical symptoms within 3 days of transfusion.
To our knowledge, our case series is the first series to describe 
the use of CCP in critically ill pediatric patients. Figlerowicz et al 
(24) published a case report describing a pediatric patient with
pancytopenia related to COVID-19 who received CCP. Unlike our
series, the patient described in this report was hemodynamically
stable and not in respiratory distress (24). Although adverse reac-
tions can be seen with plasma transfusions, including transfusion-
related lung injury, transfusion-associated circulatory overload
(TACO), and anaphylaxis (17), no reactions or complications were
seen in our patients. In a pediatric population, TACO can be a spe-
cific concern due to large volume transfusions in a small weight
patient. Joyner et al (17) analyzed key safety metrics after CCP
transfusion in 5,000 hospitalized adults with severe COVID 19 and 
found the incidence of serious adverse events to be less than 1%.
Data from other respiratory infections suggest that convalescent 
plasma is most effective when given early in the disease process 
(19). All four of our patients received CCP early in their hospitaliza-
tion (all within the first 26 hr). Patients 1 and 2 both plateaued or 
improved in their respiratory support need following transfusion 
of CCP. They were able to be managed without intubation and were 
discharged home off of all respiratory support and oxygen on HD10 
and HD7, respectively (Table 1). Discharge occurred 5–7 days after 
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the administration of CCP. Patient 4 did develop severe ARDS and 
escalated to needing intubation on HD3, but she was able to be 
extubated on HD6 (5 d after CCP) and weaned off of oxygen sup-
port on HD9. She was discharged home off of all respiratory sup-
port on HD11, 10 days after the administration of CCP (Table 1).
Patient 3 presented a challenging case. Initially, she was believed to 
have acute COVID-19 infection due to respiratory failure and positive 
PCR and thus was given CCP as respiratory support quickly escalated. 
However, as her case progressed and she was found to have IgG anti-
bodies to COVID-19 in a sample collected prior to receiving CCP, our 
diagnosis changed to MIS-C. Data are lacking on the benefit of CCP 
in critically ill patients with MIS-C. Patient 3 did improve through-
out hospitalization. She was decannulated from VA ECMO on HD9 
(7 d post CCP) and extubated the following day. She decreased on her 
respiratory support and was discharged home off of all respiratory 
support on HD24, 23 days after the administration of CCP (Table 1).
Whether the stability and eventual improvements in the 
patients would have occurred without CCP cannot be answered 
from this case series. As is common in many hospitalized and crit-
ically ill patients, all patients received other therapies in addition 
to CCP. Perhaps, the improvement in patients was related to com-
bination therapy as all patients also received immune-modulating 
drugs. Although these confounding other therapies and a small 
sample size limit our ability to assign efficacy to CCP, our case 
series demonstrates that CCP can feasibly be given to critically ill 
pediatric patients without adverse events. Additionally, all of our 
patients tolerated all therapies aimed at modulating COVID-19, 
including remdesivir and anakinra. A systematic review published 
in May of 2020 found that there are 47 ongoing studies evaluating 
convalescent plasma (10), including at our own institution. The 
Randomized Evaluation of COVID-19 therapy trial in Europe is 
a randomized control trial that is enrolling hospitalized children 
(25). Additionally, the National Institutes of Health lists another 
phase 1 study looking at the safety and pharmacokinetics of CCP 
in high risk children exposed or infected with COVID-19 which 
has not yet started enrolling (26). Our case series suggests that 
broader inclusion of pediatric patients should occur in additional 
studies as children can have severe disease with COVID-19 and 
appear to tolerate similar therapeutic modalities being tested in 
adults. Well-designed and controlled trials that include pediatric 
patients are critical to assess the safety and efficacy of CCP to this 
unique patient population.
CONCLUSIONS
We present the first case series of pediatric patients receiving CCP. 
Our results indicate that CCP is a feasible therapy for critically 
ill pediatric patients infected with SARS-CoV-2. Well-designed 
clinical trials are necessary to determine overall safety and efficacy 
of CCP and other disease modifying agents in pediatric patients.
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